Study Using 68GaGa-ABY-025 PET Imaging to Guide Treatment with HER2-Targeted Therapy in Women with Metastatic HER2-Expressing Breast Cancer
Led by Renske Altena · Updated on 2025-11-20
70
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating metastatic breast cancer in women who have received at least one prior systemic therapy. This trial focuses on using a special imaging technique called positron emission tomography PET with a tracer called 68GaGa-ABY-025 to better understand HER2 expression in tumors. The goal is to see if this precise imaging can help doctors plan treatments more effectively, particularly with the drug trastuzumab deruxtecan T-DXd, and improve patient outcomes while reducing side effects.
Participants will undergo an initial HER2-PET scan and a tumor biopsy guided by the scan results. Those with HER2-expressing tumors will receive treatment with T-DXd. After 9 to 12 weeks of treatment, a second HER2-PET scan will evaluate how well the treatment is working. An optional third scan and biopsy may be done if the disease progresses. Patients without HER2 expression will be monitored for side effects after the imaging before ending participation.
Throughout the study, patients will have biopsies of accessible metastatic lesions and tumor evaluations using CT scans. Researchers will assess treatment response, changes in HER2 expression, and quality of life at multiple points. Safety monitoring includes tracking adverse events for patients without HER2 expression. Overall, this study aims to last until disease progression or withdrawal, with follow-up assessments scheduled at key treatment milestones to understand the benefits of HER2-PET imaging combined with T-DXd therapy.
CONDITIONS
Brief Title
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Research Team
T
Thuy Tran, Associate Prof, PharmD, PhD
R
Renske Altena, Associate Professor, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Metastatic or locally advanced breast cancer with disease progression after at least one line of chemotherapy in the palliative setting, or relapse within six months after completing (neo-)adjuvant chemotherapy
Able and willing to provide written consent to participate
At least one metastatic lesion 10 mm or larger available for biopsy, or a recent biopsy (within 12 months) without HER2-targeted therapy or local radiotherapy
At least one additional metastatic lesion 10 mm or larger for treatment evaluation
WHO performance status of 2 or less
Expected survival longer than 12 weeks
Females of child-bearing potential must use adequate contraception before and during the study and for six months after the last dose; pregnancy tests are required before each administration
You will not qualify if you...
Contraindications for trastuzumab deruxtecan treatment or inability to undergo this treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
Renske Altena, Oscar P B Wiklander, Nour Susaeg Romdhani...